Table 1.
A summary of key prospective and retrospective studies evaluating sequencing of abiraterone and enzalutamide in mCRPC.
| Study | Study Type | Sequence (n) | Median PFS | Median PSA-PFS ** | Median OS |
|---|---|---|---|---|---|
| Khalaf et al. [10] |
Prospective, randomized |
AAP → ENZ (101) | - | 19·3 months (95% CI 16·0–30·5) |
28.8 months (95% CI 25.4–NR) |
| ENZ → AAP (101) | - | 15.2 months (95% CI 11.9–19.8) (p = 0.036) |
24.7 months (95% CI 18.8–34.0) (p = 0.23) |
||
| Terada et al. [11] ## |
Retrospective | AAP → ENZ (113) | - | 15.0 months (95% CI 12.6–16.3) |
30.2 months (95% CI 25.0–NR) |
| ENZ → AAP (85) | - | 9.7 months (95% CI 7.7–11.8) (p < 0.001) |
29.5 months (95% CI 24.4–NR) (p = 0.599) |
||
| Mori et al. [12] |
Retrospective | AAP → ENZ (23) | NR | 9 months | Not statistically different (p = 0.62) |
| ENZ → AAP (46) | 11 months (p = 0.043) | 7 months (p = 0.049) | |||
| Maughan et al. [11] |
Retrospective | AAP → ENZ (65) | 19.5 months (95% CI 15.5–22.3) |
17.5 months (95% CI 14.0–19.5) |
33.3 months (95% CI 2.4–NR) |
| ENZ → AAP (16) | 13.0 months (95% CI 10.3–21.2) |
12.3 months (95% CI 8.9–20.5) |
29.9 months (95% CI 18.8–NR) |
**—For Khalaf et al., the primary endpoint was time to second PSA progression, and these data are reported under median PSA-PFS column; N—number of patients; PFS—progression-free survival; OS—overall survival; AAP—abiraterone acetate and prednisone; ENZ—enzalutamide; NR - not reached; CI—confidence interval; ##—For Terada et al., PSA-PFS and OS data have been converted from days to months for consistency.